Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

CPHI Japan 2026 Takeaways: Why supply chain diversification is redefining CDMO trust in Japan
Explore how supply chain diversification is changing CDMO selection in Japan, from technical depth to global operating models. Read more.
21st May, 2026
Decoding the FDA’s AMT program through process analytical technology
Learn how process analytical technology enables advanced manufacturing technologies under the FDA AMT program and transforms pharma production. Explore the insights today.
15th May, 2026
Gene editing in 2025: from CRISPR to next generation platforms
Explore how gene editing is evolving beyond CRISPR with base editing and prime editing technologies shaping next generation therapeutics.
5th May, 2026
AI Drug Discovery: The Future of Small Molecule Design
Discover how AI drug discovery is reshaping small molecule design through faster learning cycles, better prediction, and integrated decisions.
30th Apr, 2026
Tirbanibulin and targeted dermal delivery in topical drug development
Tirbanibulin shows how ADME science, dermal delivery, and topical formulation development turn skin drugs into real therapies. Read the full Syngene perspective now.
13th Apr, 2026
Therapeutics 2.0: Veterinary Oncology and Peptide Conjugates for Companion Animal Health
Explore how peptide conjugates are advancing veterinary oncology and pet therapeutics through targeted drug delivery. Discover emerging approaches today.
13th Apr, 2026
Current Toxicology Developments: Advancing Digital Pathology in Predictive, Mechanistic, and Human-Relevant Safety Science
Explore how digital pathology is transforming predictive toxicology and safety assessment. Learn the latest approaches in modern toxicology—read more now.
9th Apr, 2026
Speed vs. quality: balancing timelines in outsourced R&D with GXP compliance
How pharma teams balance speed and GXP compliance in outsourced R&D to deliver predictabletimelines and regulatory-ready outcomes. Explore the approach.
3rd Apr, 2026
Reimagining CROs: Integrated Innovation Partnerships as the Future of Drug Discovery
Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.
26th Feb, 2026
Improving Supply Chain Resilience: HPAPI Containment And Batch Reliability In Global Pharma Manufacturing
Global pharmaceutical supply chains are under sustained pressure from rising regulatory expectations, complex molecules, and frequent disruptions across geographies. For manufacturers handling highly potent active pharmaceutical ingredients (HPAPIs), the challenge is more pronounced.
25th Feb, 2026

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details